Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: magnesium stearate; titanium dioxide; croscarmellose sodium; microcrystalline cellulose; methacrylic acid copolymer; colloidal anhydrous silica; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); gelatin; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - dimethyl fumarate msn is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: purified talc; microcrystalline cellulose; gelatin; croscarmellose sodium; titanium dioxide; triethyl citrate; colloidal anhydrous silica; magnesium stearate; methacrylic acid copolymer; methacrylic acid - ethyl acrylate copolymer (1:1); propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - dimethyl fumarate msn is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); croscarmellose sodium; methacrylic acid copolymer; purified talc; titanium dioxide; gelatin; triethyl citrate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - dimethyl fumarate msn is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: gelatin; purified talc; methacrylic acid - ethyl acrylate copolymer (1:1); colloidal anhydrous silica; triethyl citrate; methacrylic acid copolymer; titanium dioxide; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - dimethyl fumarate msn is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; povidone; croscarmellose sodium; gelatin; indigo carmine; iron oxide red; iron oxide yellow - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, modified release - excipient ingredients: brilliant blue fcf; croscarmellose sodium; methacrylic acid copolymer; polysorbate 80; purified talc; triethyl citrate; gelatin; colloidal anhydrous silica; simethicone; magnesium stearate; sodium lauryl sulfate; titanium dioxide; microcrystalline cellulose; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - tecfidera is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, modified release - excipient ingredients: colloidal anhydrous silica; gelatin; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; croscarmellose sodium; polysorbate 80; simethicone; methacrylic acid copolymer; magnesium stearate; brilliant blue fcf; microcrystalline cellulose; iron oxide yellow; triethyl citrate; sodium lauryl sulfate; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - tecfidera is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: lactose monohydrate; maize starch; purified talc; titanium dioxide; gelatin; indigo carmine; ethanol; butan-1-ol; shellac; methanol - neurontin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children aged 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. neurontin is indicated for the treatment of neuropathic pain

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phenoxymethylpenicillin, quantity: 500 mg - capsule, hard - excipient ingredients: erythrosine; titanium dioxide; sunset yellow fcf; brilliant blue fcf; magnesium stearate; gelatin; indigo carmine; allura red ac; quinoline yellow aluminium lake; iron oxide black; sd alcohol 3-a - penicilin v potassium is indicated in the treatment of mild to moderately severe infections due to penicillin v sensitive micro-organisms. therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. note: severe pneumonia, empyema, bacteraemia, pericarditis, meningitis and arthritis should not be treated with penicillin v during the acute stage. indicated surgical procedures should be performed.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phenoxymethylpenicillin, quantity: 250 mg - capsule, hard - excipient ingredients: brilliant blue fcf; magnesium stearate; titanium dioxide; erythrosine; sunset yellow fcf; carbon black; gelatin; indigo carmine; allura red ac; quinoline yellow aluminium lake; iron oxide black; sd alcohol 3-a - treatment of mild to moderately severe infections due to penicillin v sensitive micro-organisms. therapy should be guided by bacteriological studies ( including sensitivity tests) and by clinical response. note: severe pneumonia, empyema, bacteraemia, pericarditis, meningitis and arthritis should not be treated with penicillin v during the acute stage. indicated surgical procedures should be performed. the following infections will usually respond to adequate dosage of penicillin v: streptococcal infections( without bacteraemia). mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas. note: streptococci in groups a,c,g,h,l and m are very sensitive to penicillin. other groups, including group d (enterococcus) are resistant. pneumococcal infections. mild to moderately severe infections of the respiratory tract. staphylococcal infections-penicillin v sensitive. mild infections of the skin and soft tissues. note: reports indicate an increasing number of strains of staphylococci resistant to penicillin v, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. fusospirochetosis (vincent's gingivitis and pharyngitis)-mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. note: reports indicate an increasing number of strains of staphylococci resistant to penicillin v, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. fusospirochetosis( vincent's gingivitis and pharyngitis)-mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. note; necessary dental care should be accomplished in infections involving the gum tissue. medical conditions in which oral penicillin therapy is indicated as prophylaxis: for the prevention of recurrence following rheumatic fever and/or chorea-prophylaxis with oral penicillin on a continuing basis has proven bacterial endocarditis in patients with congenital and/or rheumatic heart lesions who are to undergo dental procedures or minor upper respiratory tract surgery or instrumentation. prophylaxis should be instituted on the day of the procedure and for 2 or more days following. patients who have a past history of rheumatic fever and are receiving continuous prophylaxis may harbour increased numbers of penicillin-resistant organisms; use of another prophylactic anti-infective agent should be considered. if penicillin is to be used in these patients at surgery, penicillin may be re-instituted as a prophylactic measure against the hazards of surgically induced bacteraemia. note: oral penicillin should not be used as a adjunctive prophylaxis for genito-urinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy and complications of childbirth.